Healios KKHLOSF 57 PB Ratio is 5.11 as of Jun. 29, 2026, which is 25% below its 10-year median of 6.77. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, Healios KK ranks worse than 66.4% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-29), Healios KK's share price is $1.80. Healios KK's Book Value per Share for the quarter that ended in Mar. 2026 was $0.35. Hence, Healios KK's PB Ratio of today is 5.11.
Good Sign:
Healios KK stock PB Ratio (=4.4) is close to 2-year low of 4.4.
The historical rank and industry rank for Healios KK's PB Ratio or its related term are showing as below:
HLOSF'
s PB Ratio Range Over the Past 10 Years
Min: 2.05 Med: 6.77 Max: 61.04
Current: 4.4
During the past 12 years, Healios KK's highest PB Ratio was 61.04. The lowest was 2.05. And the median was 6.77.
HLOSF's PB Ratio is ranked worse than 66.4% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs HLOSF: 4.40
During the past 12 months, Healios KK's average Book Value Per Share Growth Rate was 190.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -15.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -30.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -20.20% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Healios KK was 69.90% per year. The lowest was -47.30% per year. And the median was -18.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Healios KK PB Ratio Related Terms
Healios KK PB Ratio Historical Data
* Premium members only.
The historical data trend for Healios KK's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Healios KK's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's PB Ratio distribution charts can be found below:
* The bar in red indicates where Healios KK's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Healios KK's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Healios KK (HLOSF) has a PB Ratio of 5.11 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Healios KK and its competitors. This is 25% below median its historical median of 6.77. Over the past decade, Healios KK's PB Ratio has ranged from 2.05 to 61.04. According to the industry distribution chart, Healios KK ranks #818 out of 1232 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Healios KK's PB Ratio too high?
Healios KK's current PB Ratio of 5.11 is 25% below median its 10-year median of 6.77. Over the past 10 years, this metric has ranged from a low of 2.05 to a high of 61.04. The Biotechnology industry median PB Ratio is 2.84. Healios KK's value of 5.11 is 80.2% above this industry median. Based on the distribution chart, Healios KK ranks #818 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #818 out of 1232 companies for PB Ratio. This places Healios KK in the lower half of its industry. The industry median PB Ratio is 2.84. Healios KK's value of 5.11 is 80.2% above this benchmark. Historically, Healios KK's own PB Ratio has ranged from 2.05 to 61.04 over the past decade. While the company's 10-year median is 6.77 vs. the industry median of 2.84, Healios KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healios KK's current PB Ratio of 5.11 is 80.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Healios KK and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current PB Ratio is 5.11, which is 25% below median its own 10-year median of 6.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current PB Ratio is 5.11, which is 25% below median its 10-year median of 6.77 and 80.2% above the Biotechnology industry median of 2.84. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Healios KK (HLOSF), the current PB Ratio is 5.11 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
PB Ratio: 5.11 (25% below median its 10-year median of 6.77)
GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
Industry Position: 80.2% above the Biotechnology median (#818 of 1232)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
